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Abstract: A well-defined, one-to-one conjugate between
human serum albumin (HSA) and protamine was synthesized
and characterized as a biocompatible carrier for macromole-
cules. In circulation, the conjugate will camouflage drug mol-
ecules upon complex formation, while liberating free drug at
the desired location using a triggering mechanism. The
N-terminus of protamine was thiolated and conjugated with
the unpaired Cysteine-34 of HSA, and was purified by ion-
exchange chromatography. The molecular weight of the con-
jugate was 70.8 kDa, confirming one-to-one conjugation
between HSA (66.6 KDa) and protamine (4200 Da). Superim-
posed fluorescence spectra of native HSA and HSA–prota-
mine conjugate indicated no conformational change around
the Trp-214. The conjugate had marked reduction in hemo-
lytic and cytotoxic properties compared to protamine. When
therapeutic potential was tested using tissue plasminogen
activator as a model drug, HSA–protamine conjugate sup-
pressed the enzymatic activity by 65%, which was fully recov-
ered by a triggering agent, heparin. The construct showed
binding characteristics with activated platelets upon conjuga-
tion with a targeting peptide, demonstrating flexibility to
introduce suitable homing moiety on the surface. The camou-
flaged construct retained triggered release property in human
plasma condition. Overall, the conjugate has a good potential
to serve as a biocompatible platform for macromolecular
drugs. VC 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A:
102A: 2481–2490, 2014.
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INTRODUCTION
The use of human serum albumin (HSA) as a carrier for
therapeutic molecules has been under extensive investiga-
tion. HSA itself serves as a therapeutic agent in the events
of severe burns, hypovolemia, surgical blood loss, acute or
chronic liver failure, cardiopulmonary bypass, nutrition
support, and so forth.1 Furthermore, the ability of HSA to
bind with multiple ligands, and consequently serve as a
depot for numerous exogenous and endogenous substances
translated the use of HSA as a drug carrier from bench to
bedside. An example includes development of insulin Lev-
emirVR which contains myristic acid at the e-amino group
that binds with HSA after administration into the body,
resulting in a 50- to 70-fold increase in the half-life of the
drug.2 The albumin-paclitaxel nanoparticle, AbraxaneVR ,
becomes soluble upon intravenous administration, mimick-
ing endogenous albumin. These nanoparticles are
transported into the interstitium of a solid tumor through
the interaction of albumin with the glycoprotein gp60 that
is expressed on the endothelial cell surface.3–5 Recently,
cell penetrating albumin conjugates have also been
reported for intracellular delivery of doxorubicin.6 Further-
more, Kratz and co-workers proposed an albumin-based
pro-drug approach by conjugating doxorubicin to cysteine-
34 of endogenous HSA.7,8 The prodrug reduced the sys-
temic toxicity with a favorable cytotoxic proﬁle when the
active drug was released from albumin, either in the mild
acidic environment of the tumor extracellular compartment
or intracellularly in the acidic lysosomal compartment.9
Compared to the promising outcome of this approach with
small molecules, there are rooms for advancement in the
development of albumin-based drug carrier for macromole-
cules, such as enzyme drugs that are administered directly
into the vascular compartment.
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Therapeutic proteins, enzymes, oligoneucleotides, and
monoclonal antibodies have gained signiﬁcant attention because
of their highly speciﬁc action on the respective substrates. How-
ever, in many cases, the molecular targets are present through-
out the circulation causing the macromolecules unable to
distinguish the targets in the diseased site from those in general
tissues generating off-target effects. An effective way to over-
come this shortcoming could be targeted delivery, which, how-
ever, still carries the potential for acting on off-target substrates
while traveling in the circulation. Thus, a pro-drug approach for
these biomacromolecules is warranted to suppress the activity
of the drugs in the systemic circulation, and regenerate at the
target site. Being the most abundant plasma protein, HSA can
serve as a camouﬂage for therapeutic agents in the systemic
circulation.10,11 To that end, we propose an albumin-based pro-
drug construct for enzyme drugs in which the drug will be car-
ried by albumin via electrostatic interaction that will be
disrupted by a triggering agent upon reaching the target. As a
model macromolecule, we have used tissue plasminogen activa-
tor (tPA) that produces enzymatic action by converting plasmin-
ogen to plasmin, which further degrades ﬁbrin mesh to restore
blood ﬂow to an occluded vessel. However, tPA possesses life-
threatening bleeding risk because of its indiscriminate action on
plasminogen.12 Therefore, a prodrug approach to minimize
ubiquitous plasmin generation while maximizing tPA’s exposure
at the clot site could signiﬁcantly attenuate bleeding complica-
tion and enhance therapeutic outcome. Whereas the accumula-
tion of the agent at the clot site can be achieved by using a
suitable homing moiety, regeneration of activity remains a criti-
cal challenge because of lack of triggering environment, that is,
pH, temperature, or reducing agent, during a thrombotic event.
As heparin is commonly used in the therapeutic management of
thrombotic events, we have designed the construct such that
the regeneration of activity can be achieved by heparin adminis-
tration. Hence, a one-to-one conjugate between albumin and
protamine was developed (Fig. 1). On the other hand, tPA, the
most common thrombolytic agent, was modiﬁed to introduce a
series of negative charges so that it forms an electrostatic com-
plex with the protamine moiety of the albumin–protamine con-
jugate. We chose the homing moiety based on the interaction of
ﬁbrinogen with integrin GPIIb/IIIa that is expressed on acti-
vated platelets, the underlying factor of aggregation and forma-
tion of occlusive thrombus. Ware et al. reported the C-terminal
gamma chain peptide sequence of ﬁbrinogen, CQQHHLGGAK-
QAGDV, as the central structural segment responsible for the
binding,13 and hence was used as targeting moiety. Thus, the
construct will accumulate on the thrombus following which
therapeutically active tPA will be released upon interaction with
subsequently administered heparin. In the current work, we
have synthesized and puriﬁed albumin–protamine conjugate,
characterized for vascular and hemo-compatibility and demon-
strated the feasibility to be used for a targeted prodrug
construct for thrombolytic enzyme.
MATERIALS AND METHODS
Materials
HSA (from human blood source), protamine, ﬁbrinogen,
plasminogen, aldrithiol (2,20-Dithiopyridine 2,20-Dipyridyldi-
sulﬁde), dithiothreitol (DTT) were purchased from Sigma-
Aldrich (St. Louis, MO). N-Succinimidyl1,3-(2-pyridyldithio)
propionate (SPDP) was obtained from Molecular Biosciences
(Boulder, CO). tPA was purchased from Genentech (Genen-
tech, South San Francisco, CA). LMWH was obtained from
Eisai (Woodcliff Lake, NJ). The plasmin speciﬁc chromogenic
substrate S-2251 was obtained from Chromogenix (Lexing-
ton, MA). Fluorescein isothiocyanate (FITC) was purchased
from Fisher Scientiﬁc (Pittsburgh, PA). The 7-mers of gluta-
mate oligopeptide (CEEEEEEE) and the targeting peptide
sequence 14-mers of the C-terminal peptide (CQQHHLGGAK-
QAGDV) from the C-terminus of ﬁbrinogen gamma chain
were obtained from EZBiolab (Carmel, IN). All the cell
culture related materials were obtained from American
Type Cell Collection (ATCC; Manassas, VA). All other buffers
and chemical reagents were purchased from Sigma-Aldrich
and of reagent grade.
Activation of N-terminus proline of protamine
Protamine (10 mg) was taken in a scintillation vial into
which 770 mL of 2M NaCl dissolved in 20 mM phosphate
FIGURE 1. Graphical representation of one-to-one conjugate prepara-
tion via Cys-34 of HSA and N-terminus (secondary amine) of prota-
mine. The three-dimensional structure of HSA was generated by PPG:
the Protein Picture Generator http://bioserv.rpbs.jussieu.fr/PPG; DINO:
Visualizing Structural Biology (2002) http://www.dino3d.org.21 Atomic
coordinates were downloaded from the Protein Data Bank, accession
number 4iw2. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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buffer was added. The mixture was gently stirred at room
temperature for 10 min. Separately, 120 mg of polyethylene
glycol-600 was dissolved in 770 mL of 100 mM phosphate
buffer and added to protamine solution. Once protamine is
completely dissolved, SPDP, dissolved in 550 mL dimethylfor-
mamide (DMF), was added drop-wise at a feed-ratio of 5,
10, 15, and 20-fold excess of protamine. The reaction was
continued for 4 h at room temperature, followed by quench-
ing with 100 mL of 100 mM glycine. Excess SPDP was puri-
ﬁed by Fast Protein Liquid Chromatography (FPLC, Biologic
Duo Flow, Biorad) using ion-exchange CM-Sepharose column
(GE Healthcare) with elution buffer (A) 20 mM phosphate
buffer and (B) 2 mM NaCl1 20 mM phosphate at pH 7.4. To
quantify the yield of activated protamine, 900 mL of the col-
lected sample was taken in a quartz cuvette and absorbance
was measured at 343 nm by Diode array spectrophotometer
(HP 8453A, Olis). Then, 100 mL of 0.5M DTT solution was
added and, following 15 min of incubation, the absorbance
at 343 was again measured. The release of pyridyl-2-thione
upon treatment of DTT was calculated to determine the
extent of protamine activation.
Synthesis and puriﬁcation of HSA–protamine conjugate
HSA (10 mg) was dissolved in 20 mM phosphate buffer at
pH 7.2 from which 500 mL was taken and added drop wise
to 500 mL of activated protamine (protamine-PDP) solution.
The reaction kinetic was monitored by Diode array spectro-
photometer at 343 nm by measuring the release of
pyridine-2-thione with time. Once the reaction progression
was conﬁrmed, the feed-ratio was optimized by introducing
1, 2, 3, and 4-fold molar excess of HSA to the activated prot-
amine and incubating at room temperature for 2 h with
mild shaking. The HSA–protamine conjugate was then puri-
ﬁed in one-step using ion-exchange CM-Sepharose column
with the same elution buffer A and B as mentioned in Acti-
vation of N-terminus proline of protamine" section. The
yield of the conjugate was determined by UV spectroscopy
at 280 nm.
Determination of molecular weight and ﬂuorescence
spectra of HSA–protamine conjugate
The molecular weight of the prepared HSA–protamine
conjugate was determined by electrospray mass spectros-
copy (Agilent 6520 Q-TOF). An aliquot of 40 mL sample at a
concentration of 1 mg/mL was loaded into the autosampler
vial from which 5 mL was injected into a C-8 poroshell
column. Buffer A, composed of 5% acetonitrile with 0.1%
formic acid / 95% water with 0.1% formic acid, was run
through the sample loaded column for 2 min at a ﬂow rate
of 0.5 mL/min. Then a gradient to 100% acetonitrile with
0.1% formic acid was run over 10 min. The mass spectrom-
eter was run in positive ion mode, with reference mass cor-
rection on a dual ESI source. The data were processed with
Agilent’s MassHunter software. To compare the prepared
HSA–protmaine conjugate with native HSA (1 mg/mL), a
similar run was performed keeping all the parameters same
as that of the sample. For ﬂuorescence spectroscopic study,
a sample (1 mg/mL) of HSA and HSA–protamine conjugate
was taken in a cuvette with 1-cm path length and measure-
ment was performed on Hitachi F-2500 ﬂuorescence spec-
trophotometer. The spectrum was recorded in the range of
300–400 nm using excitation wavelength of 295 nm.
Hemolysis of protamine-conjugated HSA carrier
Hemolysis of the prepared HSA–protamine was monitored,
which could be originated from the cationic protamine moi-
ety. Human blood sample was collected from Coffee Memo-
rial Blood Center (Amarillo, TX). An aliquot of 100 mL of
blood cells were taken and diluted to 1 mL with saline. The
cells were washed three times using centrifugation (Legend
Micro 17R, Thermo Scientiﬁc) and the ﬁnal volume was
made 1 mL. The cells were further diluted 10 times from
which 100 mL was taken in each eppendorf tube into which
protamine or HSA–protamine conjugate was added at a ﬁnal
protamine concentration of 10 mg/mL. The ﬁnal volume of
1 mL was incubated at 37C for different time points.
Deionized water and saline was used as positive and nega-
tive controls, respectively. Following incubation, the samples
were centrifuged at 800g for 2 min and the supernatants
were analyzed for hemolysis by measuring absorbances at
540 nm on a spectrophotometer.
Cytotoxicity study of prepared carrier system
The cytotoxicity of HSA–protamine conjugate was tested
with arterial (pulmonary) smooth muscle cells using MTT
assay.14,15 Cells were cultured in Dulbecco’s Modiﬁed Eagle’s
Medium containing Fetal Bovine Serum and penicillin/strep-
tomycin. 50,000 cells were seeded on 96-well ﬂat bottom
plate and kept overnight for settling down. On the following
day, protamine or HSA–protamine conjugate was separately
added to the wells at a concentration range from 0 to 1
mg/mL equivalent of protamine, and incubated for 4 h at
37C. The culture media was then replaced by 100 mL of
fresh media containing 0.5 mg/mL MTT solution, and incu-
bated for another 4 h. After gently removing the MTT solu-
tion, the crystalline precipitate was dissolved in 100 mL of
dimethylsulfoxide (DMSO; molecular biology grade) and
absorbance was measured at 570 nm. The percent of viable
cells were calculated by the following equation:
%of Viable cells5 Atreated2AMTTð Þ= Acontrol2AMTTð Þ3100
HSA–protamine conjugate in the triggered-release
approach for thrombolytic macromolecules
The proof-of-principle triggered-release system for macro-
molecules with our prepared HSA–protamine conjugate was
tested using tPA as a model drug. To introduce electronega-
tive functionality, tPA was conjugated with low molecular
weight heparin (LMWH) by previously described method.10
HSA–protamine conjugate at 50-fold excess of tPA was incu-
bated with tPA for 30 min at room temperature to facilitate
electrostatic interaction between LMWH and protamine moi-
eties. The amidolytic activity of tPA upon complex formation
with HSA–protamine was measured by Chromogenic
assay.16 Brieﬂy, 1.3 lM of substrate S-2251, 0.24 lM
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plasminogen and 0.5 lg/mL tPA dissolved in 50 mM Tris
HCl containing 50 mM NaCl with 0.01% Tween 80 at pH 7.2
was taken in a 300 lL well of 96-well plate. The initial rate
of hydrolysis of S-2251 by plasmin generated from plasmin-
ogen by tPA was determined by measuring the absorbance
at 405 nm at different time intervals using a micro-plate
reader (SynergyMx, Biotek). The slope of absorbance against
square of time (DA min22) was expressed as the initial rate
of S-2251 hydrolysis. To assess heparin-mediated triggered
release, the assay was also performed in the presence of 0.4
m/mL of heparin.
Binding study of homing-peptide decorated
HSA–protamine conjugate with activated platelets
The homing peptide, CQQHHLGGAKQAGDV, was conjugated
to the primary amines of HSA of the conjugate. Brieﬂy,
SPDP, 20-fold excess of HSA, was dissolved in DMF and
added drop-wise to the HSA–protamine conjugate. Following
30 min incubation at room temperature, excess SPDP was
removed by size-exclusion chromatography, and the result-
ing puriﬁed thiol-reactive conjugate was incubated with the
homing peptide for 30 min at room temperature. Finally,
the homing-peptide decorated HSA–protamine was again
puriﬁed by size-exclusion chromatography. The binding
characteristic of the conjugate with activated-platelets were
tested by ﬂuorescence microscopy.17,18 Human platelets
(1.68 3 109 platelets/mL of plasma) were collected from
Coffee Memorial blood center (Amarillo, TX) and were iso-
lated by centrifuging 1 mL of platelet-rich plasma at 400g
for 15 min at 25C. After removing the supernatant, plate-
lets were re-suspended in PBS containing 1% Bovine Serum
Albumin (BSA). The sample was diluted to make a suspen-
sion containing 250,000 platelets per mL, which was then
adsorbed onto collagen-coated glass cover-slips at room
temperature for 1 h and washed thrice with PBS. To conﬁrm
the adhesion of platelet monolayer on cover-slips, cells were
stained with FITC-tagged anti-GPIIb/IIIa monoclonal anti-
body (eBioscience, CA, USA), and subsequently observed
under ﬂuorescence microscopy (with magniﬁcation of 10 3
60 3 1.5 (overall 9003). FITC-labeled peptide-linked cam-
ouﬂaged tPA construct was incubated with the adsorbed
platelets for 1 h in dark at room temperature. Fluorescent
construct without the homing peptide was also incubated as
a control. All incubations were carried out in the presence
of 5 mM CaCl2 solution under mild shaking to facilitate acti-
vation of platelet.
Stability of the construct in human plasma and blood
environment
Fresh human plasma and blood samples were collected
from coffee memorial blood center (Amarillo, TX). To test
the stability of the electrostatic interaction between anion-
modiﬁed tPA and HSA–Protamine conjugate, albumin-
camouﬂaged tPA was incubated with plasma for 30 min at
37C. An aliquot of 50 mL of the incubated plasma sample
was then taken and added to a well (96-well plate) to per-
form Chromogenic assay as described previously (section
HSA–protamine conjugate in the triggered-release approach
for thrombolytic macromolecules). To evaluate the triggered
release proﬁle, a heparin (0.4 m/mL) treated group was also
tested with the camouﬂaged tPA group.
Statistical analysis
All data were presented as the mean6 SD. One-way ANOVA
was performed to compare among the groups and analyze
the statistical signiﬁcance. Post-hoc analyses were
conducted using Tukey’s comparison (GraphPad Prism,
version 5.0, GraphPad Software, San Diego, CA). p-values
less than 0.05 were considered statistically signiﬁcant.
RESULTS
N-terminal thiolation of protamine
As protamine does not contain any lysyl residues, the only
site to introduce the SPDP linker at neutral to slightly alka-
line condition is the N-terminal proline, a secondary
amine.19 However, addition of SPDP in either ethanol or
DMF caused precipitation of protamine when the reaction
media was phosphate buffered saline, which was later
solved performing the reaction in 2M NaCl stabilized with
PEG-600. FPLC chromatographic data demonstrate that the
puriﬁcation method effectively removed unreacted SPDP
[Fig. 2(A)]. Protamine activation was qualitatively conﬁrmed
by the release of pyridine-2-thione at 343 nm upon treat-
ment with DTT [Fig. 2(B)]. Quantiﬁcation indicates that as
much as 41% of protamine was activated by SPDP when
5-fold excess of SPDP was used. The extent of activation
increased to 63% when amount of SPDP was increased by
2-fold. However, further increase in SPDP mole% did not
produce any increase in protamine activation [Fig. 2(C)].
Hence, a 10-fold excess of SPDP over protamine was
selected as the optimum feed ratio.
Preparation of HSA–protamine conjugate
Addition of HSA solution into activated protamine spontane-
ously released pyridine-2-thione [Fig. 3(A)], indicating the
reaction between the Cys-34 of HSA and activated prota-
mine. When protamine solution, without SPDP modiﬁcation,
was reacted with HSA, no reaction was evident by spectros-
copy. The kinetics of the reaction revealed that it reaches a
plateau at around 10 min [Fig. 3(B)]. The one-step puriﬁca-
tion method effectively separated unreacted HSA, unreacted
activated protamine, and the HSA–protamine conjugate.
Because of no afﬁnity towards CM-sepharose column,
unreacted HSA elutes immediately after being injected,
which was conﬁrmed by separate injection (data not
shown). The reason that HSA–protamine conjugate elutes
separately from unreacted activated protamine may be
attributed to the slight decrease in binding afﬁnity of the
bulky HSA-protamine to CM-Sepharose resin. With the
increasing feed-ratio of HSA over protamine-PDP, an
increase in the peak for HSA–protamine conjugate was
observed with corresponding decrease in the protamine-
PDP peak, suggesting the depletion of protamine with
increasing production of the conjugate [Fig. 3(C)]. A 4:1
molar ratio of HSA:protamine resulted with almost complete
depletion of protamine. Quantiﬁcation of HAS–protamine
2484 ABSAR ET AL. SERUM ALBUMIN–PROTAMINE CONJUGATE FOR BIOCOMPATIBLE PLATFORM
conjugate also demonstrated that the yield of the conju-
gate increased with increasing HSA molar ratio from 1:1
to 4:1 as that of protamine [Fig. 3(D)]. Thus, a 4-fold
excess of HSA was selected for further preparation of the
conjugate.
Characterization of HSA–protamine conjugate
The goal of this conjugation reaction is the formation of
one-to-one conjugate between HSA and protamine to avoid
heterogeneity in drug delivery application. The electrospray
mass spectroscopy data revealed that the molecular weight
of the conjugate was around 70.8 KDa [Fig. 4(B)]. As the
molecular weight of native HSA was found to be 66.6 kDa
[Fig. 4(A)] and that of protamine was 4.2 kDa, the weight of
the conjugate demonstrates a 1:1 conjugation. Furthermore,
the intrinsic ﬂuorescence spectrum of HSA–protamine was
analyzed to determine if protamine conjugation had altered
the conformation of HSA around the tryptophan residue
(Trp 274). Upon excitation at 295 nm, both native HSA and
the HSA–protamine conjugate demonstrated maximum emis-
sion intensity at 340 nm. Moreover, the emission proﬁle
was nearly identical and resulted in superimposed spectra
between native HSA and HSA–protamine conjugate
[Fig. 4(C)], indicating no quenching of the intrinsic ﬂuores-
cence of Trp-214 residue of HSA. This indicates that confor-
mation of the hydrophobic binding pocket in the second
a-helix domain of HSA remained unaffected after conjuga-
tion with protamine.20
Biocompatibility of HSA–protamine conjugate
The potential hemolysis, if occurs because of a high posi-
tive charge density of protamine, can limit the application
of the proposed conjugate as a drug delivery tool. The
hemolysis study demonstrated that protamine, in the form
of HSA–protamine conjugate, had produced no lytic effect
and was comparable to that of saline at equivalent prota-
mine concentration of 10 mg/mL, whereas native prota-
mine, at the same concentration, caused considerable
hemolysis [Fig. 5(A)]. As the maximum concentration of
protamine in human blood with our proposed delivery
system would be 4 mg/mL, we claim the conjugate hemo-
compatible. Further, the compatibility study in the vascula-
ture revealed that the cell viability was almost unaffected
with HSA–protamine conjugate as demonstrated by >90%
survival at a concentration equivalent to 1 mg/mL of prot-
amine. However, cell viability was signiﬁcantly compro-
mised (only 20% survival) at similar concentration of
native protamine [Fig. 5(B)]. Thus both the hemocompati-
bility and cellular toxicity studies indicate that the pro-
posed conjugate is unlikely to exert any deleterious effect
at a concentration that will be applied for its use as a
therapeutic cargo.
Proof-of-principle application of HSA–protamine
conjugate as a carrier for therapeutic macromolecule
The sole purpose of this conjugate is to mask the enzymatic
activity of a macromolecule, tPA in this case, by HSA, and to
regenerate the activity using therapeutic steady-state
concentration of heparin. In order to form the electrostatic
complex between tPA and HSA, we have previously func-
tionalized tPA with electronegative charge.10 When the
HSA–protamine conjugate was introduced to tPA with elec-
tronegative functionality, 65% of tPA’s activity was
suppressed (Fig. 6). However, when heparin (0.4 m/mL) was
added to the “camouﬂaged” tPA construct, the activity was
fully regenerated, suggesting that while HSA masked tPA’s
activity by forming electrostatic complex with
FIGURE 2. (A) Purification of PDP-activated protamine by ion-
exchange chromatography using CM-sepharose column. The 1 mL
reaction mixture was eluted using buffer A: 20 mM phosphate, pH
7.4; B: 20 mM phophate pH 7.412M NaCl. (B) Release of pyridyl-2-
thione measured at 343 nm upon treatment of PDP-activated prota-
mine with DTT. The green and blue lines represent chromatographic
traces of PDP-activated protamine before and after addition of DTT,
respectively. (C) % Yield of PDP-activated protamine with increasing
mol:mol feed ratio of SPDP to protamine. [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
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electronegative tPA surface, administration of heparin dis-
rupted the construct and liberated free tPA because of its
strong afﬁnity towards protamine. This observation indi-
cates that if the camouﬂaged structure can be directed
towards thrombus using a homing mechanism, the systemic
“lytic” effect of tPA can be attenuated and the thrombolytic
action can potentially be regenerated by heparin, which is
commonly administered during thrombosis management.
Binding of homing peptide-decorated HSA–protamine
conjugate with activated platelets
The proposed targeted/triggered delivery system using
HSA–protamine conjugate is contingent upon the accumula-
tion of the macromolecule on its site of action, which in this
case is thrombus. Hence, the surface of HSA–protamine con-
jugate was decorated with the homing peptide that binds
with GPIIb/IIIa present on activated platelets during
FIGURE 3. (A) Spontaneous reaction between HSA and PDP-activated protamine as monitored by the release of pyridyl-2-thione at 343 nm. The
absorbance at 343 increased with increasing time. (B) Time course of HSA–protamine-PDP reaction: a 3D spectroscopic trace of the reaction
from diode-array spectrophotometer demonstrating a saturation point at around 10 min. (C) One-step purification of HSA–protamine conjugate
from unreacted HSA and protamine-PDP using ion-exchange chromatography. The 1-mL reaction mixture was eluted on a CM-sepharose col-
umn with elution buffer A: 20 mM phosphate, pH 7.4; B: 20 mM phosphate pH 7.41 2M NaCl. The green, red, violet, and blue lines represent 1,
2, 3, and 4-fold molar excess of HSA to protamine, respectively. (D) Yield of HSA–protamine conjugate with increasing molar excess of HSA to
that of protamine. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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thrombotic event. Fluorescence microscopic image revealed
that FITC-labeled peptide-grafted conjugate bound to the
activated platelet surface as demonstrated by the staining of
almost all the cells (Fig. 7). However, ﬂuorescent conjugate
without the homing peptide did not exhibit any binding
with platelets. In the control experiment, activation of plate-
lets was conﬁrmed by the staining of the cells with FITC-
labeled anti-GPIIb/IIIa antibody. Thus the binding study
suggests that HSA–protamine conjugate can be decorated
with a suitable homing peptide to direct the cargo at a
desired site.
Stability of the HSA-mediated construct in human
plasma
The electrostatic interaction between HSA–protamine conju-
gate and anion-functionalized tPA was stable enough to
mask the enzymatic activity of tPA in human plasma
(Fig. 8). Moreover, the characteristic regeneration of activity
was retained upon the treatment with heparin. The activity
of the camouﬂaged tPA after heparin addition was 3-fold
higher than that of plain tPA. As heparin stimulates tPA
activity both in vitro and in vivo,21 results were compared
with the control group that was also treated with heparin.
FIGURE 4. Electrospray mass spectroscopy of (A) native HSA and (B) HSA–protamine conjugate, indicating molecular weight of each species.
(C) Overlapping intrinsic fluorescence emission spectra of HSA and HSA–protamine conjugate. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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Thus, it was conﬁrmed that the higher enzymatic activity of
tPA in the heparin-triggered group was not only because of
heparin stimulation but also the removal of the albumin
camouﬂage.
DISCUSSION
Use of HSA as a delivery tool has made seminal contribution
in the ﬁeld of controlled drug delivery. Albumin micro-
spheres, for instance, have shown potential to deliver both
small and large therapeutic molecules.7 Because of its natu-
ral abundance in blood, albumin-mediated delivery system
can be ideal in designing a triggered release system for
therapeutic macromolecules where the activity of the thera-
peutic cargo should be protected in blood. The key chal-
lenge in developing such delivery systems is masking the
activity of the drug in the systemic circulation in a reversi-
ble manner so that pharmacologic action can be triggered at
the disease site. As, unlike intracellular environment, blood
environment lacks environmental triggers, such as pH or
reducing environment, regeneration of activity is often difﬁ-
cult. A classic example of protecting a protein in blood
includes PEGylation of proteins to increase circulation half-
life. However, covalent attachment of PEG on the protein
surface, ironically, often results in diminished drug activity
because of steric hindrance created by PEG molecules that
prevent the target molecule to interact and produce phar-
macological action, as was the case with tPA.22 Our pro-
posed HSA–protamine conjugate is designed to address the
above mentioned limitations in which the bulky albumin
moiety will serve as a “camouﬂage” for the drug in the sys-
temic circulation, whereas the positively charged protamine
will facilitate formation of an electrostatic complex with the
drug. Depending on the therapeutic application, a triggering
agent can be chosen to disrupt the construct and liberate
free drug at the site of action.
Preparing a one-to-one conjugate between two different
proteins is desirable to avoid potential heterogeneity that
might result from numerous reactive functional groups pres-
ent on their surface. Considering the presence of the single,
relatively reactive secondary amine group on the
N-terminus (proline) of protamine, and the free thiol group
FIGURE 5. (A) Hemo-compatibility of HSA–protamine conjugate. The
extent of hemolysis was determined by measuring the absorbance of
released hemoglobin at 540 nm. An equivalent protamine concentra-
tion of 10 mg/mL was used for both protamine and HSA–protamine
groups (n5 3). (B) Cell viability of HSA–protamine conjugate as deter-
mined by MTT assay using arterial (pulmonary) smooth muscle cells
(n5 8). Data represent mean6SD. ***p< 0.001. [Color figure
can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
FIGURE 6. HSA–protamine conjugate in suppression and regeneration
of activity of thrombolytic agent, tPA. (A) Chromogenic assay deter-
mining enzymatic action of tPA using plasmin-specific substrate
S-2251. Experimental condition: HSA–protamine 0.2 mM, S-2251 1.2
mM, plasminogen 0.24 mM, tPA 0.5 mg/mL, and heparin 0.4 m/mL.
(B) Enzymatic activity of tPA upon complex formation with HSA–prot-
amine and subsequent regeneration with heparin. The activity was
calculated from the slope of the enzymatic assay. Data represent
mean6SD (n-3). ***p< 0.001.
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on Cys-34 of HSA, reaction scheme was designed to link
these two so that any heterogeneity can be avoided. How-
ever, a critical challenge was activation of the N-terminal
proline of protamine to make it thiol-reactive. Upon stabili-
zation of protamine solution with high concentration of
NaCl and PEG-600, a signiﬁcant amount (63%) of protamine
was linked to SPDP that eventually demonstrated a sponta-
neous reaction with the Cys-34 of HSA. The chromato-
graphic method employed to purify protamine from
unreacted SPDP could not distinguish between unreacted
and reacted protamine. However, it is important to note
that, following conjugation with HSA, only the HSA–prota-
mine conjugate was collected leaving the activated and non-
activated protamine that was eluted later [third fraction in
the chromatogram; Fig. 3(C)]. The second fraction was the
desired HSA–protamine conjugate, as evident by the electro-
spray mass spectrometry. The selection was initially based
on partial charge screening because of the presence of albu-
min that would allow the conjugate to elute relatively ear-
lier than native protamine, and also from the observation
that upon increasing concentration of albumin, the second
fraction reaches a higher peak with consequent reduction of
the later fraction, which is assumed to be the unreacted
protamine. Moreover, the collected fraction was ﬁnally con-
ﬁrmed as HSA–protamine conjugate by determining the
molecular weight that was found to be consistent with the
sum of the weights of HSA and protamine.
The hemolysis and cell viability study further suggest
that the possible deleterious effect of cationic protamine is
diminished by the presence of albumin. We argue that the
immunogenicity associated with protamine use would also
be attenuated upon conjugation with albumin. This argu-
ment is supported by earlier observation that conjugation of
PEG molecules to protamine attenuates complement activa-
tion and subsequent immunogenic response19 because of
the shielding effects created by PEG. As albumin, being
several-folds larger than protamine, is conjugated to
N-terminus of protamine, a similar nonimmunogenic proﬁle
is expected. It should also be noted that albumin is the
most abundant protein in human plasma that, along with its
size, makes it an excellent choice as a “camouﬂaging
moiety”. Moreover, HSA offers a high degree of ﬂexibility for
surface modiﬁcation that allows introducing homing moi-
eties to direct the construct towards any desired site of
action.
The proof-of-concept study using tPA showed convincing
outcome in camouﬂaging tPA’s enzymatic action upon com-
plex formation with HSA–protamine conjugate, followed by
regeneration of activity using therapeutic steady state hepa-
rin concentration. Therefore, the lytic action of tPA will be
impeded in the systemic circulation but will be potentiated
at the clot site, and hence will attenuate bleeding complica-
tion that can occur with conventional tPA therapy. The con-
struct was designed such that tPA’s action can be triggered
using a triggering agent that is already included in the ther-
apeutic modality of thrombosis management. Therefore,
unlike other triggered-release systems, any external trigger,
for example ultrasound, is not required. It should be noted
that in the plasma condition, activity of the camouﬂaged tPA
FIGURE 8. Stability of HSA–protamine mediated camouflaged tPA in
human plasma. (A) Amidolytic activity of tPA determined after incuba-
tion in human plasma. (B) Enzymatic activity of tPA upon camouflag-
ing action of HSA–protamine and triggered release by heparin. Data
represent mean6SD (n53). *p< 0.05, **p< 0.01.
FIGURE 7. Binding of surface decorated HSA–protamine conjugate
with activated platelets observed under fluorescence microscope
(9003 magnification). The bright field images indicate the adsorbed
platelets while the FITC images staining with peptide-linked HSA–
protamine conjugate. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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after regeneration in human plasma was even higher than
that of native tPA. Based on the concept of steric stabiliza-
tion, the shielding effect created by the HSA moiety can
potentially attenuate PAI-1 mediated inactivation of tPA in
plasma, while no such protection is available for the native
tPA. This observation is in accordance with the hypothesis
that, using HSA–protamine, the macromolecules will be pro-
tected not only from producing systemic action, but also
from circulating inactivating molecules which eventually
could offer a larger amount of active drug in the site of
action, thereby minimizing the dose.
Along with thrombolytic agents, a potential application
for this construct could be the delivery of anticancer drug
for which minimization of systemic exposure is warranted.
Moreover, the utility of albumin carrier to solid tumor
through endothelial binding with GP60 is well docu-
mented.3–5 In this case, regeneration of activity can be
achieved by reduction of disulﬁde bond between HSA and
protamine at the intracellular compartment, offering active
chemotherapeutic agent at the cancerous site. Similar
approach can also be applied to intracellular delivery of
genetic materials by protecting them in the systemic circula-
tion, making this system a potentially widely applicable, bio-
compatible carrier of therapeutic macromolecules.
CONCLUSION
In this study, we have proposed a novel albumin-based
delivery system for therapeutic macromolecules. A one-to-
one conjugate between HSA and protamine was synthesized
and characterized for physical properties and biocompatibil-
ity. A proof-of-principle study using thrombolytic protein,
tPA, as a model drug demonstrated that HSA–protamine
conjugate can form a stable electrostatic complex with func-
tionalized tPA and signiﬁcantly mask its enzymatic activity.
A suitable triggering agent, in this case heparin, disrupts the
construct and regenerates tPA’s activity. Hence, the proposed
HSA–protamine conjugate holds the potential towards a
newer triggered release approach for therapeutic proteins.
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